We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction (STEMI) (COMFORTABLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00962416
Recruitment Status : Completed
First Posted : August 20, 2009
Last Update Posted : March 30, 2016
Swiss National Science Foundation
Information provided by:
University Hospital Inselspital, Berne

Brief Summary:

Stent study:

Treatment of patients with acute myocardial infarction with drug eluting stents (DES) is effective but there remain concerns regarding the long-term safety and adverse effects on the adjacent arterial wall. The biolimus-eluting Biomatrix stent addresses the issues by incorporating modifications as a biodegradable polymer and a drug application solely to the abluminal stent surface. While clinical data about the biolimus-eluting stent show a favorable safety and efficacy profile, they require confirmation in a dedicated randomised trial in the subset of patients with STEMI. Therefore, the study is designed to compare the safety and efficacy of biolimus-eluting Biomatrix stent as compared to a bare metal stent of otherwise identical design in a prospective, multicenter, randomized, controlled superiority trial in patients with acute ST-elevation myocardial infarction.

Stent and Plaque Imaging Substudy:

In a substudy of the above mentioned stent trial, the investigators will perform a prospective, multicenter, longitudinal cohort study of 100 consecutive STEMI patients undergoing urgent coronary angiography and will employ high-resolution Optical Coherence Tomography (OCT) imaging technology and intra-vascular ultrasound and virtual histology (IVUS-VH) of the culprit STEMI lesions pre- and postprocedural as well as at a 13 months follow up. Assessment of vascular wall responses, including volumetric measurements of vessel, stent, lumen, peri-stent plaque, and intimal hyperplasia, indices of remodeling, stent expansion, and stent-vessel wall apposition in response to biolimus-eluting and bare-metal stent implantation will be performed. Moreover, IVUS, IVUS-VH and OCT will be performed in all three epicardial vessels in order to quantify and map the number, frequency and distribution of ruptured plaques at baseline and follow-up and quantify the morphological changes of ruptured and vulnerable plaques at baseline and follow-up and quantify the morphological changes over time in response to standard medical treatment. Therefore, new insight regarding the frequency, distribution, composition and evolution of coronary artery plaques and their prognostic impact on patients clinical outcome can be expected from the present study. Since patients suffer from a recurrent ischemic event rate of 5-10% during the first year, these findings may have important therapeutic implications for the medical treatment of affected patients to further reduce the risk of recurrence and improve prognosis.

Condition or disease Intervention/treatment Phase
ST-elevation Myocardial Infarction Device: Biolimus eluted from an erodable stent coating (Biomatrix) Device: bare-metal stent (Gazelle) Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1161 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of Biolimus Eluted From an Erodable Stent Coating With Bare-Metal Stents in Acute ST-Elevation Myocardial Infarction and In Vivo 3-Vessel Assessment of Time-Related Changes of Culprit and Non-Culprit Lesions by IVUS/OCT in AMI
Study Start Date : September 2009
Actual Primary Completion Date : January 2012
Actual Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Arm Intervention/treatment
Active Comparator: 1
Biolimus eluting Stent (Biomatrix)
Device: Biolimus eluted from an erodable stent coating (Biomatrix)
The Biolimus-eluting stent (Biomatrix) has a corrugated ring design available in six and nine cell models and is laser cut from 316L VM stainless steel hypotube. The nominal dosage of Biolimus A9 goes from 133 to 442 microgram. The producer of the drug is Nippoon Kayaku Co., Ltd Takasaki Plant, 239, Iwahanamachi, Takasaki-shi, Gumma 370-1028 Japan. The biodegradable polymer is polylactic acid, which has become one of the most commonly used biodegradable polymers. Polylactic acid, its co-polymers, and mixtures have been evaluated in the preclinical, and clinical studies, revealing a favorable biocompatability profile. The polymer has been demonstrated to be safe when used as implant of drug release-control polymer for both animals and humans.

Active Comparator: 2
Bare metal stent (Gazelle)
Device: bare-metal stent (Gazelle)
A bare-metal stent of identical design without surface application of polymer and drug.

Primary Outcome Measures :
  1. Major adverse cardiac events (MACEs) in the overall population, defined as the composite of cardiac death, target-vessel related myocardial infarction (Q-wave and non-Q-wave), or ischemia-driven target lesion revascularization within 12 months [ Time Frame: 30 days, 6 months, 1,2 and 5 years ]

Secondary Outcome Measures :
  1. All deaths [ Time Frame: 30 days, 6 months, 1,2 and 5 years ]
  2. Clinically and non-clinically indicated target lesion revascularizations [ Time Frame: 30 days, 6 months, 1, 2 and 5 years ]
  3. Stent thrombosis ARC defined [ Time Frame: 30 days, 1,2 and 5 years ]
  4. Stent strut coverage as assessed by OCT [ Time Frame: 13 months ]
  5. Malapposition as assessed by OCT/IVUS [ Time Frame: 13 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age equal or more than 18 years
  • Chest pain > 10 minutes
  • Primary pci
  • ST-segment elevation of > 1 mm in > 2 contiguous leads, or (presumably new) left bundle branch block, or true posterior MI with ST depression of > 1 mm in > 2 contiguous anterior leads
  • Presence of at least one acute infarct artery target vessel with one or more coronary artery stenoses in a native coronary artery from 2.25-4 mm in diameter that can be covered with 1-multiple stents

Exclusion Criteria:

  • Female of childbearing potential (age 50 and last menstruation within the last 12 months), who did not underwent tubal ligation, ovariectomy or hysterectomy
  • Known intolerance to aspirin, clopidogrel, heparin, stainless steel, biolimus or contrast material
  • Inability to provide informed consent
  • Currently participating in another trial before reaching first endpoint
  • Mechanical complication of acute myocardial infarction
  • Acute myocardial infarction secondary to stent thrombosis
  • Planned surgery within 6 months of PCI unless dual antiplatelet therapy is maintained throughout the perisurgical period
  • Noncardiac comorbid conditions are present with life expectancy 1 year or that may result in protocol malcompliance
  • History of bleeding diathesis or known coagulopathy
  • Use of Coumadin
  • Additional for Imaging Substudy:

    • Age > 90 years
    • Hemodynamic instability
    • Renal failure
    • OCT/IVUS technically not feasible
    • Any patient in whom angiography demonstrates the infarct lesion to be at the site of a previously implanted stent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00962416

Layout table for location information
Department of Cardiology
Bern, Switzerland, 3010
Dep. of Cardiology
Geneva, Switzerland, 1211
Dep. of Cardiology
Lugano, Switzerland, 6900
Dep. of Cardiology
University of Lausanne, Switzerland, 1011
Dep. of Cardiology
Zürich, Switzerland, 8091
Sponsors and Collaborators
University Hospital Inselspital, Berne
Swiss National Science Foundation
Layout table for investigator information
Study Chair: Stephan Windecker, Professor of Cardiology Dep. of Cardiology, University Hospital Bern
Study Director: Lorenz Räber, MD Dep. of Cardiology, University Hospital Bern
Study Director: Peter Jüni, Professor of Biostatistics Dep. of Social and Preventive Med., University Bern
Study Director: Hector Garcia Garcia, MD Erasmus Thoraxcenter Rotterdam, The Netherlands
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Prof. Stephan Windecker, Cardiology Department, University Hospital Bern
ClinicalTrials.gov Identifier: NCT00962416    
Other Study ID Numbers: 137/09
1373 ( Other Identifier: Inselspital )
First Posted: August 20, 2009    Key Record Dates
Last Update Posted: March 30, 2016
Last Verified: March 2016
Keywords provided by University Hospital Inselspital, Berne:
Drug eluting stent
Biodegradable stent
ST-elevation myocardial infarction
Coronary artery disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Infarction
ST Elevation Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases